ND-011992

• Description:

  ND-011992 is a reversible, selective quinazoline-type inhibitor targeting quinone reductases and quinol oxidases. ND-011992 inhibits respiratory complex I and bo3 oxidase in addition to bd-I and bd-II oxidases in E. coli strain BL21*Δcyo with the IC50 of 0.12, 2.47, 0.63 and 1.3 μM, respectively. ND-011992 can be used for tuberculosis study[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319

• Target:

  Bacterial; Mitochondrial Metabolism

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/nd-011992.html

• Purity:

  98.26

• Solubility:

  DMSO : 40 mg/mL (ultrasonic; adjust pH to 4 with 1 M HCl)

• Smiles:

  FC(F)(F)C(C=C1)=CC=C1OC(C=C2)=CC=C2NC3=NC=NC4=CC=CC=C43

• Molecular Formula:

  C21H14F3N3O

• Molecular Weight:

  381.35

• Precautions:

  H302, H315, H319

• References & Citations:

  [1]Kägi J, et al. Exploring ND-011992, a quinazoline-type inhibitor targeting quinone reductases and quinol oxidases. Sci Rep. 2023;13 (1) :12226. Published 2023 Jul 28. doi:10.1038/s41598-023-39430-w

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2446880-46-0]